Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

ClinicalTrials.gov ID: NCT06405087

Public ClinicalTrials.gov record NCT06405087. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits because of bowel swelling (inflammation) are needed and has an impact on the quality of life of children and teenagers who received vedolizumab SC. In this study, participants who responded well to the treatment with vedolizumab SC in the parent study (VedolizumabSC-3003 \[NCT06100289\]) will continue to be treated with vedolizumab SC. Participants who did not respond well to the treatment with vedolizumab SC in the parent study or who received corticosteroids in the last 4 weeks of the parent study will not receive vedolizumab SC in this study but will be followed for up to 2 years after the last treatment with vedolizumab SC in the parent study. During the study, participants will visit their study clinic several times.

Study identification

NCT ID
NCT06405087
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Takeda
Industry
Enrollment
70 participants

Conditions and interventions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
2 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 26, 2025
Primary completion
Aug 11, 2030
Completion
Aug 11, 2030
Last update posted
Jun 21, 2026

2025 – 2030

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Phoenix Childrens Hospital Phoenix Arizona 85016 Not yet recruiting
Loma Linda University Loma Linda California 92350 Not yet recruiting
Children's Hospital of Orange County Orange California 92868 Not yet recruiting
Stanford Children's Health Palo Alto California 94304 Not yet recruiting
Advocate Children's Hospital Park Ridge Park Ridge Illinois 60068 Not yet recruiting
Childrens Hospital of Michigan Detroit Michigan 48201 Not yet recruiting
Atlantic Health - Morristown Medical Center Morristown New Jersey 07960 Not yet recruiting
New York Presbyterian Hospital New York New York 10029 Not yet recruiting
University Children's Clinic Cleveland Ohio 44106 Not yet recruiting
Cleveland Clinic Cleveland Ohio 44195 Not yet recruiting
The University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 Recruiting
Penn State Health Milton South Hershey Medical Center Hershey Pennsylvania 17033 Not yet recruiting
Medical University of South Carolina Charleston South Carolina 29425 Not yet recruiting
Multicare Health System Institute for Research and Innovation Tacoma Washington 98405 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06405087, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06405087 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →